| Dr Ann M Granchelli, MD | |
|
1400 Jackson St, Denver, CO 80206-2761 | |
| (303) 388-4461 | |
| (303) 270-2206 |
| Full Name | Dr Ann M Granchelli |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 15 Years |
| Location | 1400 Jackson St, Denver, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609019751 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| National Jewish Health | Denver, CO | Hospital |
| Saint Joseph Hospital | Denver, CO | Hospital |
| Rose Medical Center | Denver, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| National Jewish Health | 4587577028 | 220 |
News Archive
A team from the University of Leicester, led by Professor Melanie Davies from the Department of Cardiovascular Sciences and Professor Kamlesh Khunti from the Department of Health Sciences, has developed an easy way for people to assess their risk of having diabetes. Working in partnership with Diabetes UK, the largest diabetes charity in the country, and University Hospitals of Leicester NHS Trust, they have produced the first diabetes risk assessment that can be used in a multi-ethnic population.
A team of radiation oncologists at the Zucker School of Medicine at Hofstra/Northwell in the United States aimed to determine if COVID-19 infected cancer patients receiving radiation therapy (RT) have any different outcome than non-infected patients.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.
Researchers have developed a type of wearable, non-invasive electronic device that can monitor vital signs such as heart rate and respiration at the same time it records a person's activity level, opening new opportunities for biomedical research, diagnostics and patient care.
UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
› Verified 2 days ago
| Entity Name | National Jewish Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326015777 PECOS PAC ID: 4587577028 Enrollment ID: O20031110000757 |
News Archive
A team from the University of Leicester, led by Professor Melanie Davies from the Department of Cardiovascular Sciences and Professor Kamlesh Khunti from the Department of Health Sciences, has developed an easy way for people to assess their risk of having diabetes. Working in partnership with Diabetes UK, the largest diabetes charity in the country, and University Hospitals of Leicester NHS Trust, they have produced the first diabetes risk assessment that can be used in a multi-ethnic population.
A team of radiation oncologists at the Zucker School of Medicine at Hofstra/Northwell in the United States aimed to determine if COVID-19 infected cancer patients receiving radiation therapy (RT) have any different outcome than non-infected patients.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.
Researchers have developed a type of wearable, non-invasive electronic device that can monitor vital signs such as heart rate and respiration at the same time it records a person's activity level, opening new opportunities for biomedical research, diagnostics and patient care.
UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ann M Granchelli, MD 1400 Jackson St, Denver, CO 80206-2761 Ph: (303) 388-4461 | Dr Ann M Granchelli, MD 1400 Jackson St, Denver, CO 80206-2761 Ph: (303) 388-4461 |
News Archive
A team from the University of Leicester, led by Professor Melanie Davies from the Department of Cardiovascular Sciences and Professor Kamlesh Khunti from the Department of Health Sciences, has developed an easy way for people to assess their risk of having diabetes. Working in partnership with Diabetes UK, the largest diabetes charity in the country, and University Hospitals of Leicester NHS Trust, they have produced the first diabetes risk assessment that can be used in a multi-ethnic population.
A team of radiation oncologists at the Zucker School of Medicine at Hofstra/Northwell in the United States aimed to determine if COVID-19 infected cancer patients receiving radiation therapy (RT) have any different outcome than non-infected patients.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.
Researchers have developed a type of wearable, non-invasive electronic device that can monitor vital signs such as heart rate and respiration at the same time it records a person's activity level, opening new opportunities for biomedical research, diagnostics and patient care.
UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
› Verified 2 days ago
Katrina Wagoner-hursh, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1835 Franklin St, Denver, CO 80218 Phone: 303-338-4545 | |
Emily Martin Jones, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8111 E Lowry Blvd, Denver, CO 80230 Phone: 720-848-0000 | |
Dr. Jesus Heliodoro Hermosillo Rodriguez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Margaret Hay, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1601 E 19th Ave Ste 3100, Denver, CO 80218 Phone: 303-863-0300 Fax: 303-863-7014 | |
Dr. Alan W Burgess, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1601 E 19th Ave Ste 6000, Denver, CO 80218 Phone: 303-861-7001 Fax: 303-861-8624 | |
Dr. Sahibzada Mohsin Shah, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 777 Bannock St, Denver, CO 80204 Phone: 303-436-6000 | |
Shyam M Parkhie, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 130 Rampart Way, 300b, Denver, CO 80230 Phone: 720-343-1562 Fax: 720-343-1563 |